CYTK250117P35000
- 0.15
- 0.000.00%
Cytokinetics Newsroom
Cytokinetics Says European Regulator Validated Its Application for Cardiomyopathy Drug Candidate
Cytokinetics Announces EMA Has Validated MAA for Aficamten
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Express News | Cytokinetics Inc - FDA Sets Pdufa Target Action Date for Aficamten Nda as Sept 26, 2025
Express News | Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
Why Cytokinetics Stock Was a Nearly 5% Winner Today
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China
Cytokinetics Announces Sanofi's Acquisition Of Aficamten Rights For HCM Treatment In Greater China
Express News | Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi
Express News | Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $82
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $82
Express News | Cytokinetics Inc : RBC Raises Target Price to $82 From $80
Cytokinetics Insider Sold Shares Worth $369,639, According to a Recent SEC Filing
Insider Sale: EVP Research & Development of $CYTK (CYTK) Sells 5,300 Shares
Truist Financial Sticks to Its Buy Rating for Cytokinetics (CYTK)